Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB12 (Epysqli) Pharmacokinetics and Safety in Healthy Subjects
NCT03722329Phase 1Completed
- Sponsor
- Samsung Bioepis
- Start
- Nov 2018
- Primary completion
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SB12 in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) (3 arms), sponsored by Samsung Bioepis. Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to Infinity. Started Nov 2018; status: completed.
02
Drugs
SB12
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT03722329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03722329.